Gastroenterology Research and Practice / 2012 / Article / Tab 1

Research Article

Probiotics, Symptoms, and Gut Microbiota: What Are the Relations? A Randomized Controlled Trial in Subjects with Irritable Bowel Syndrome

Table 1

IBS symptom scores, the relative proportion of the components of the fecal microbiota, and the diversity indexes in the four parts of the trial. Results are given as mean (SD).

VariablesRun-in period1st treatment periodWashout period2nd treatment period

IBS symptom score (range 0–15)
 Active treatment 1st period6.17 (1.07)6.18 (1.83)6.58 (2.55)5.14 (2.12)
 Placebo treatment 1st period6.26 (2.20)5.61 (1.31)5.80 (2.61)6.77 (1.85)
Bacteroides
 Active treatment 1st period0.07 (0.05)0.07 (0.06)0.07 (0.07)0.12 (0.10)
 Placebo treatment 1st period0.19 (0.17)0.21 (0.16)0.16 (0.12)0.14 (0.10)
Faecalibacterium
 Active treatment 1st period0.54 (0.23)0.53 (0.21)0.47 (0.26)0.46 (0.26)
 Placebo treatment 1st period0.44 (0.23)0.56 (0.21)0.54 (0.15)0.61 (0.25)
Lachnospiraceae
 Active treatment 1st period0.38 (0.22)0.40 (0.17)0.46 (0.23)0.42 (0.24)
 Placebo treatment 1st period0.37 (0.21)0.23 (0.14)0.30 (0.16)0.26 (0.18)
“Common” Simpson’s D
 Active treatment 1st period0.46 (0.09)0.48 (0.10)0.46 (0.13)0.48 (0.11)
 Placebo treatment 1st period0.52 (0.20)0.51 (0.23)0.54 (0.12)0.46 (0.18)
“Alternative” Simpson’s D
 Active treatment 1st period321 (382)59 (19)67 (21)28 (10)
 Placebo treatment 1st period921353389
“Alternative” Shannon’s H
 Active treatment 1st period6.42 (0.80)5.86 (0.03)5.73 (0.27)5.47 (0.36)
 Placebo treatment 1st period6.096.425.796.12

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.